Skip to content

Study · Animal study (in vivo) · mouse · 2022

9 results

Guanylyl Cyclase-B Dependent Bone Formation in Mice is Associated with Youth, Increased Osteoblasts, and Decreased Osteoclasts.

Wagner BM, Robinson JW, Prickett TCR, Espiner EA, Khosla S, Gaddy D, Suva LJ, Potter LR

Calcified tissue international10 Aug 2022Cited by 5 (Europe PMC)

PMID35947145 (opens in a new tab)DOI10.1007/s00223-022-01014-7 (opens in a new tab)PepBankPUB-35947145
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In wild type mice, BMN-111 increased osteocalcin compared with no BMN-111.

    In plain wordsIn mice, BMN-111 increased osteocalcin compared with no BMN-111.

    Peptide
    Vosoritide
    Outcome
    IncreaseOsteocalcin
    Study

    mousen: not reported in source

    12-week-old wild type mice
    Comparator
    No BMN-111
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injection · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    We found that BMN-111 treated mice had elevated levels of osteocalcin and collagen 1 C-terminal telopeptide (CTX) as well as increased osteoblasts and osteoclasts.
    1 context sentence
    Summary · context
    Here, we injected 12-week-old, wild type mice once daily for 28 days with or without BMN-111 (Vosoritide), a proteolytically resistant CNP analog.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In wild type mice, BMN-111 increased CTX compared with no BMN-111.

    In plain wordsIn mice, BMN-111 increased CTX compared with no BMN-111.

    Peptide
    Vosoritide
    Outcome
    IncreaseCollagen 1 C-terminal telopeptide
    Study

    mousen: not reported in source

    12-week-old wild type mice
    Comparator
    No BMN-111
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injection · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    We found that BMN-111 treated mice had elevated levels of osteocalcin and collagen 1 C-terminal telopeptide (CTX) as well as increased osteoblasts and osteoclasts.
    1 context sentence
    Summary · context
    Here, we injected 12-week-old, wild type mice once daily for 28 days with or without BMN-111 (Vosoritide), a proteolytically resistant CNP analog.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In wild type mice, BMN-111 increased osteoblasts compared with no BMN-111.

    In plain wordsIn mice, BMN-111 increased osteoblasts compared with no BMN-111.

    Peptide
    Vosoritide
    Outcome
    IncreaseOsteoblasts
    Study

    mousen: not reported in source

    12-week-old wild type mice
    Comparator
    No BMN-111
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injection · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    We found that BMN-111 treated mice had elevated levels of osteocalcin and collagen 1 C-terminal telopeptide (CTX) as well as increased osteoblasts and osteoclasts.
    1 context sentence
    Summary · context
    Here, we injected 12-week-old, wild type mice once daily for 28 days with or without BMN-111 (Vosoritide), a proteolytically resistant CNP analog.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In wild type mice, BMN-111 increased osteoclasts compared with no BMN-111.

    In plain wordsIn mice, BMN-111 increased osteoclasts compared with no BMN-111.

    Peptide
    Vosoritide
    Outcome
    IncreaseOsteoclasts
    Study

    mousen: not reported in source

    12-week-old wild type mice
    Comparator
    No BMN-111
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injection · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    We found that BMN-111 treated mice had elevated levels of osteocalcin and collagen 1 C-terminal telopeptide (CTX) as well as increased osteoblasts and osteoclasts.
    1 context sentence
    Summary · context
    Here, we injected 12-week-old, wild type mice once daily for 28 days with or without BMN-111 (Vosoritide), a proteolytically resistant CNP analog.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In wild type mice, BMN-111 increased tibial Rank ligand mRNA compared with no BMN-111.

    In plain wordsIn mice, BMN-111 increased tibial Rank ligand mRNA compared with no BMN-111.

    Peptide
    Vosoritide
    Outcome
    IncreaseRank ligand mRNA
    Study

    mousen: not reported in source

    12-week-old wild type mice
    Comparator
    No BMN-111
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injection · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    In BMN-111 injected mice, tibial mRNAs for Rank ligand and osteoprotegrin were increased and decreased, respectively, whereas sclerostin mRNA was elevated 400-fold, consistent with increased osteoclast activity and decreased osteoblast activity.
    1 context sentence
    Summary · context
    Here, we injected 12-week-old, wild type mice once daily for 28 days with or without BMN-111 (Vosoritide), a proteolytically resistant CNP analog.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In wild type mice, BMN-111 decreased tibial osteoprotegerin mRNA compared with no BMN-111.

    In plain wordsIn mice, BMN-111 decreased tibial osteoprotegerin mRNA compared with no BMN-111.

    Peptide
    Vosoritide
    Outcome
    DecreaseOsteoprotegerin mRNA
    Study

    mousen: not reported in source

    12-week-old wild type mice
    Comparator
    No BMN-111
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injection · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    In BMN-111 injected mice, tibial mRNAs for Rank ligand and osteoprotegrin were increased and decreased, respectively, whereas sclerostin mRNA was elevated 400-fold, consistent with increased osteoclast activity and decreased osteoblast activity.
    1 context sentence
    Summary · context
    Here, we injected 12-week-old, wild type mice once daily for 28 days with or without BMN-111 (Vosoritide), a proteolytically resistant CNP analog.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In wild type mice, BMN-111 elevated tibial sclerostin mRNA 400-fold compared with no BMN-111.

    In plain wordsIn mice, BMN-111 elevated tibial sclerostin mRNA 400-fold compared with no BMN-111.

    Peptide
    Vosoritide
    Outcome
    IncreaseSclerostin mRNA
    Study

    mousen: not reported in source

    12-week-old wild type mice
    Comparator
    No BMN-111
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injection · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    In BMN-111 injected mice, tibial mRNAs for Rank ligand and osteoprotegrin were increased and decreased, respectively, whereas sclerostin mRNA was elevated 400-fold, consistent with increased osteoclast activity and decreased osteoblast activity.
    1 context sentence
    Summary · context
    Here, we injected 12-week-old, wild type mice once daily for 28 days with or without BMN-111 (Vosoritide), a proteolytically resistant CNP analog.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In wild type mice, BMN-111 did not elevate mineral apposition rates compared with no BMN-111.

    In plain wordsIn mice, BMN-111 did not elevate mineral apposition rates compared with no BMN-111.

    Peptide
    Vosoritide
    Outcome
    No significant changeMineral apposition rate
    Study

    mousen: not reported in source

    12-week-old wild type mice
    Comparator
    No BMN-111
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injection · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Mineral apposition rates and trabecular bone mass were not elevated in response to BMN-111.
    1 context sentence
    Summary · context
    Here, we injected 12-week-old, wild type mice once daily for 28 days with or without BMN-111 (Vosoritide), a proteolytically resistant CNP analog.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In wild type mice, BMN-111 did not elevate trabecular bone mass compared with no BMN-111.

    In plain wordsIn mice, BMN-111 did not elevate trabecular bone mass compared with no BMN-111.

    Peptide
    Vosoritide
    Outcome
    No significant changeTrabecular bone mass
    Study

    mousen: not reported in source

    12-week-old wild type mice
    Comparator
    No BMN-111
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · injection · 28 daysAs given in this study (mouse).

    Source sentences

    Summary
    Mineral apposition rates and trabecular bone mass were not elevated in response to BMN-111.
    1 context sentence
    Summary · context
    Here, we injected 12-week-old, wild type mice once daily for 28 days with or without BMN-111 (Vosoritide), a proteolytically resistant CNP analog.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.